Vascular Biogenics Ltd (VBLT)

[gr8db8]

VB-111 discussed in KOL was also interesting. "If we meet the primary endpoint (survival) it should be the only trial to put this drug on the market."

Known but worth mentioning again .. Thyroid trial: patients have exhausted every treatment in thyroid ... tail: 40% alive after 3.7 years.

Interim results estimated in mid-year .. "later it gets the better for us ... means not enough patients died." Top line data end of year or beginning of next year (again, later the better).

By combining therapy (PD-L1) can maximize effect of VB-111. <<- I think we found the other therapy for the combo trial.